Sanitary Pad To Detect HPV Using Menstrual Blood
PadX-HPV's special chip is engineered to capture and retain cervical cells that contain HPV.
It detects 24 types of HPV from a single menstrual blood sample, including 18 high-risk strains.
No speculum. No clinic visit. No discomfort.
99.2%* Accuracy. Clinically Validated. In Market Now.
THREE Simple Steps.
Life-Changing Protection.
1. Wear the Pad
Use PadX-HPV as a regular pad on your heaviest flow day for at least 4 hours, or until the central rectangular collection area is half-soaked with menstrual blood.
2. Send to Lab
Seal the pad in the provided zip-lock bag, complete the consent form, and mail it back to our partner medical laboratory. Samples remain stable at room temperature for 30 days, no cold chain transportation.
3. Digital Results
Receive your secure digital report via email within 3 working days.
BREAKING BARRIERS IN WOMEN'S HEALTH
Validated Precision. Trusted Results.
WomenX Biotech harnesses the power of menstrual blood to deliver accurate cervical screening that prioritises comfort, privacy, and dignity.
We hope PadX shall eliminate all fear and inconvenience caused by traditional Pap smears while maintaining rigorous clinical standards.
20,000+
Women’s Life Journeys Supported
90%
User Satisfaction Rate
90%
of Users Prefer PadX for Their Next Routine Screening
Future of Women's Health:
Closing the Global Screening Gap
Traditional cervical screening is plagued by logistical barriers, clinical anxiety, and cultural taboos—leaving millions undiagnosed.
Do You Know?
"95% of cervical cancer is caused by persistent infection of high-risk HPV."
World Health Organisation. (2024, March 5). Cervical cancer.
But the reality is...
Cervical screening coverage across the Asia-Pacific is
31.4%
In South-East Asia, the figure drops further to
29.1%
Leading to 350,000 cervical cancer cases (pa) in APAC.
Bruni, L., Albero, G., Serrano, B., Mena, M., Collado, J. J., Gómez, D., Muñoz, J., Bosch, F. X., & de Sanjosé, S. (2023). Human papillomavirus and related diseases in Asia-Pacific (Summary Report). ICO/IARC Information Centre on HPV and Cancer.
Our Mission:
Boost the screening rate to
80%
with PadX
Our Reach & Expansion
Our journey to empower women’s health begins in Hong Kong, with rapid expansion plans already underway to reach new global communities.
Sign up to be notified as soon as PadX arrives in your region.
Media
Awards
Supported by
Join WomenX - The Future of Women Health Tech
Be our distributor
Partner with us to introduce the future of non-invasive screening to your market. Together, we can close the preventative care gap on a global scale.
Be our investor
We are driving a paradigm shift in women's wellness. Join forward-thinking investors and strategic partners in accelerating the global adoption of our breakthrough technology.